PneumRx Inc.

PneumRx Inc. is a medical technology company focused on innovative solutions for respiratory diseases, providing advanced therapeutic devices aimed at improving patient outcomes in healthcare. Founded in 2004 and headquartered in Mountain View, US, PneumRx Inc. specializes in developing technologies for respiratory conditions.

The company was acquired by BTG in December 2014 for up to USD 475 mn and has completed three deals to date. PneumRx Inc. specializes in a range of innovative solutions designed to meet the evolving needs of its customer base. Its core product offerings focus on advanced technology platforms that streamline operational processes, enhance user engagement, and improve overall efficiency.

These products are developed to address specific pain points within industries such as healthcare, finance, and logistics, ultimately aiming to optimize workflows and reduce costs for end-users. The company has established a diverse clientele, including small to medium-sized enterprises and large corporations, which leverage its solutions to achieve their business objectives. Geographically, the company markets its products across North America, Europe, and Asia-Pacific, ensuring wide accessibility to its technology. Revenue generation for PneumRx Inc.

is primarily driven through a combination of subscription-based services and direct-to-consumer sales. Clients typically engage in annual or monthly subscription models, granting them access to the company's flagship technology solutions, which focus on enhancing operational efficiency and user experience. In addition to subscriptions, partnerships with key industry players further bolster revenue through collaborative initiatives and integrated solutions. Specific pricing plans are structured around the scale of deployment, allowing for flexibility based on client needs, with customizable packages that reflect the unique requirements of each sector served.

This transactional framework not only ensures steady revenue streams but also fosters long-term relationships with clients who benefit from ongoing support and product enhancements. While specific upcoming products and their release dates are not mentioned, recent funding from the Trade Sale in December 2014, which amounted to USD 475 mn, is expected to support PneumRx's strategic initiatives. The company aims to explore expansion into new geographic markets, specifically targeting increased presence in Europe and Asia-Pacific by the end of the upcoming fiscal year.